Literature DB >> 29209047

IBD in 2017: Development of therapy for and prediction of IBD - getting personal.

Raja Atreya1, Britta Siegmund2.   

Abstract

Mesh:

Year:  2017        PMID: 29209047     DOI: 10.1038/nrgastro.2017.166

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN: 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  10 in total

1.  Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial.

Authors:  Sudarshan Paramsothy; Michael A Kamm; Nadeem O Kaakoush; Alissa J Walsh; Johan van den Bogaerde; Douglas Samuel; Rupert W L Leong; Susan Connor; Watson Ng; Ramesh Paramsothy; Wei Xuan; Enmoore Lin; Hazel M Mitchell; Thomas J Borody
Journal:  Lancet       Date:  2017-02-15       Impact factor: 79.321

2.  Is intensity the solution for FMT in ulcerative colitis?

Authors:  Britta Siegmund
Journal:  Lancet       Date:  2017-02-15       Impact factor: 79.321

3.  In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease.

Authors:  Raja Atreya; Helmut Neumann; Clemens Neufert; Maximilian J Waldner; Ulrike Billmeier; Yurdagül Zopf; Marcus Willma; Christine App; Tino Münster; Hermann Kessler; Stefanie Maas; Bernd Gebhardt; Ralph Heimke-Brinck; Eva Reuter; Frank Dörje; Tilman T Rau; Wolfgang Uter; Thomas D Wang; Ralf Kiesslich; Michael Vieth; Ewald Hannappel; Markus F Neurath
Journal:  Nat Med       Date:  2014-02-23       Impact factor: 53.440

4.  Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.

Authors:  Brian G Feagan; William J Sandborn; Geert D'Haens; Julián Panés; Arthur Kaser; Marc Ferrante; Edouard Louis; Denis Franchimont; Olivier Dewit; Ursula Seidler; Kyung-Jo Kim; Markus F Neurath; Stefan Schreiber; Paul Scholl; Chandrasena Pamulapati; Bojan Lalovic; Sudha Visvanathan; Steven J Padula; Ivona Herichova; Adina Soaita; David B Hall; Wulf O Böcher
Journal:  Lancet       Date:  2017-04-12       Impact factor: 79.321

5.  Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn's Disease: A Phase 2a Study.

Authors:  Bruce E Sands; Jingjing Chen; Brian G Feagan; Mark Penney; William A Rees; Silvio Danese; Peter D R Higgins; Paul Newbold; Raffaella Faggioni; Kaushik Patra; Jing Li; Paul Klekotka; Chris Morehouse; Erik Pulkstenis; Jörn Drappa; René van der Merwe; Robert A Gasser
Journal:  Gastroenterology       Date:  2017-04-05       Impact factor: 22.682

6.  Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.

Authors:  Brian G Feagan; William J Sandborn; Christopher Gasink; Douglas Jacobstein; Yinghua Lang; Joshua R Friedman; Marion A Blank; Jewel Johanns; Long-Long Gao; Ye Miao; Omoniyi J Adedokun; Bruce E Sands; Stephen B Hanauer; Severine Vermeire; Stephan Targan; Subrata Ghosh; Willem J de Villiers; Jean-Frédéric Colombel; Zsolt Tulassay; Ursula Seidler; Bruce A Salzberg; Pierre Desreumaux; Scott D Lee; Edward V Loftus; Levinus A Dieleman; Seymour Katz; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2016-11-17       Impact factor: 91.245

7.  Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci.

Authors:  Andre Franke; Dermot P B McGovern; Jeffrey C Barrett; Kai Wang; Graham L Radford-Smith; Tariq Ahmad; Charlie W Lees; Tobias Balschun; James Lee; Rebecca Roberts; Carl A Anderson; Joshua C Bis; Suzanne Bumpstead; David Ellinghaus; Eleonora M Festen; Michel Georges; Todd Green; Talin Haritunians; Luke Jostins; Anna Latiano; Christopher G Mathew; Grant W Montgomery; Natalie J Prescott; Soumya Raychaudhuri; Jerome I Rotter; Philip Schumm; Yashoda Sharma; Lisa A Simms; Kent D Taylor; David Whiteman; Cisca Wijmenga; Robert N Baldassano; Murray Barclay; Theodore M Bayless; Stephan Brand; Carsten Büning; Albert Cohen; Jean-Frederick Colombel; Mario Cottone; Laura Stronati; Ted Denson; Martine De Vos; Renata D'Inca; Marla Dubinsky; Cathryn Edwards; Tim Florin; Denis Franchimont; Richard Gearry; Jürgen Glas; Andre Van Gossum; Stephen L Guthery; Jonas Halfvarson; Hein W Verspaget; Jean-Pierre Hugot; Amir Karban; Debby Laukens; Ian Lawrance; Marc Lemann; Arie Levine; Cecile Libioulle; Edouard Louis; Craig Mowat; William Newman; Julián Panés; Anne Phillips; Deborah D Proctor; Miguel Regueiro; Richard Russell; Paul Rutgeerts; Jeremy Sanderson; Miquel Sans; Frank Seibold; A Hillary Steinhart; Pieter C F Stokkers; Leif Torkvist; Gerd Kullak-Ublick; David Wilson; Thomas Walters; Stephan R Targan; Steven R Brant; John D Rioux; Mauro D'Amato; Rinse K Weersma; Subra Kugathasan; Anne M Griffiths; John C Mansfield; Severine Vermeire; Richard H Duerr; Mark S Silverberg; Jack Satsangi; Stefan Schreiber; Judy H Cho; Vito Annese; Hakon Hakonarson; Mark J Daly; Miles Parkes
Journal:  Nat Genet       Date:  2010-12       Impact factor: 38.330

Review 8.  Common disorders are quantitative traits.

Authors:  Robert Plomin; Claire M A Haworth; Oliver S P Davis
Journal:  Nat Rev Genet       Date:  2009-10-27       Impact factor: 53.242

9.  Genome-wide association study identifies distinct genetic contributions to prognosis and susceptibility in Crohn's disease.

Authors:  James C Lee; Daniele Biasci; Rebecca Roberts; Richard B Gearry; John C Mansfield; Tariq Ahmad; Natalie J Prescott; Jack Satsangi; David C Wilson; Luke Jostins; Carl A Anderson; James A Traherne; Paul A Lyons; Miles Parkes; Kenneth G C Smith
Journal:  Nat Genet       Date:  2017-01-09       Impact factor: 41.307

10.  Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease.

Authors:  Nathaniel R West; Ahmed N Hegazy; Benjamin M J Owens; Samuel J Bullers; Bryan Linggi; Sofia Buonocore; Margherita Coccia; Dieter Görtz; Sébastien This; Krista Stockenhuber; Johanna Pott; Matthias Friedrich; Grigory Ryzhakov; Frédéric Baribaud; Carrie Brodmerkel; Constanze Cieluch; Nahid Rahman; Gerhard Müller-Newen; Raymond J Owens; Anja A Kühl; Kevin J Maloy; Scott E Plevy; Satish Keshav; Simon P L Travis; Fiona Powrie
Journal:  Nat Med       Date:  2017-04-03       Impact factor: 53.440

  10 in total
  1 in total

1.  A blood-based prognostic biomarker in IBD.

Authors:  Daniele Biasci; James C Lee; Nurulamin M Noor; Diana R Pombal; Monica Hou; Nina Lewis; Tariq Ahmad; Ailsa Hart; Miles Parkes; Eoin F McKinney; Paul A Lyons; Kenneth G C Smith
Journal:  Gut       Date:  2019-04-27       Impact factor: 23.059

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.